Fisher Wallace (2024)
About this raise
Fisher Wallace, with a valuation of $104.1 million, is raising funds on Dealmaker Securities. The company manufactures and sells wearable medical devices for mood and sleep disorders, including insomnia, anxiety, and depression. Fisher Wallace’s most recent product, OAK, works as a super device for depression and positions its patent-pending technology as the most rapid treatment for depression. The company has generated $40 million in lifetime revenue through selling 100,000 units and has 14,000 prescribers. Kelly Roman and Charles Fisher founded Fisher Wallace in August 2019. The current crowdfunding campaign has a minimum target of $10,010.11 and a maximum target of $1 million. The campaign proceeds will be used for clinical research, regulatory affairs, manufacturing, product development, and operations.
Investment Overview
Invested : $413,448
Deal Terms
Total Commitments
- Platform
- DealMaker Securities
- Start Date
- 03/28/2024
- Close Date
- 04/18/2024
$10,010
$1,001,011
$289
Equity - Common
Series B
RegCF
$11.11
$104,100,000
Company & Team
Company
- Year Founded
- 2019
- Industry
- Fitness & Wellness
- Tech Sector
- Distribution Model
- B2B/B2C
- Margin
- High
- Capital Intensity
- Low
Financials
- Revenue +12% YoY
- $4,739,387
- Monthly Burn
- $589,479
-
Runway
- 0.2 months
- Gross Margin
- 77%
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $13,084,146
- VC Backed?
- Yes
| Offering Name | Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|---|
| Fisher Wallace Labs | 03/12/2025 | DealMaker Securities | $108,800,000 | $188,189 | Convertible Note | Funded | RegCF |
| Fisher Wallace Labs | 01/02/2025 | DealMaker Securities | $108,250,000 | $217,434 | Equity - Common | Funded | RegCF |
| Fisher Wallace Labs | 10/17/2024 | DealMaker Securities | $106,700,000 | $276,274 | Equity - Common | Funded | RegCF |
| Fisher Wallace | 07/02/2024 | DealMaker Securities | $106,000,000 | $237,234 | Equity - Common | Funded | RegCF |
| Fisher Wallace | 04/18/2024 | DealMaker Securities | $104,100,000 | $413,448 | Equity - Common | Funded | RegCF |
| Fisher Wallace | 03/12/2024 | DealMaker Securities | $102,658,809 | $469,069 | Equity - Common | Funded | RegCF |
| Fisher Wallace | 01/24/2024 | DealMaker Securities | $102,170,000 | $532,202 | Equity - Common | Funded | RegCF |
| Fisher Wallace Laboratories | 10/04/2023 | StartEngine | $100,280,000 | $493,354 | Equity - Common | Funded | RegA+ |
| Fisher Wallace | 02/20/2023 | StartEngine | $81,567,588 | $1,281,201 | Equity - Common | Funded | RegCF |
| Fisher Wallace Laboratories | 09/01/2022 | StartEngine | $81,236,323 | $357,719 | Equity - Common | Funded | RegCF |
| Fisher Wallace Laboratories | 05/27/2022 | StartEngine | $80,048,889 | $1,279,724 | Equity - Common | Funded | RegCF |
| Fisher Wallace Laboratories | 10/26/2021 | StartEngine | $40,000,000 | $5,010,683 | Equity - Common | Funded | RegA+ |
| Fisher Wallace Laboratories | 03/09/2020 | StartEngine | $15,000,000 | $1,056,480 | Equity - Common | Funded | RegCF |
Growth Charts
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Valuation History
Price per Share History
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.